Approaches to develop therapeutics to treat frontotemporal dementia.
Level 5 - mechanism / opinion, no new human data
Narrative review of disease mechanisms and therapeutic strategies with no empirical human data
PubMed 31962288 · doi:10.1016/j.neuropharm.2020.107948
What was done
This narrative review synthesizes the biological mechanisms underlying frontotemporal degeneration (FTD) caused by GRN gene mutations and discusses strategies for identifying genetic and chemical modulators to restore brain progranulin (PGRN) levels.
What was found
The abstract reports no numerical data, statistical estimates, or experimental effect sizes. It details the pathological cascade of PGRN insufficiency—including lysosome dysfunction, TDP-43 accumulation, microglial activation, and neurodegeneration—and notes its potential relevance to Alzheimer's disease.
Why it matters
Frontotemporal dementia has no disease-modifying therapies; targeting progranulin deficits focuses directly on the causal pathology of familial GRN-mutant disease.
Limits
The review provides no original human data or quantitative trial results. Detailed mechanisms, specific candidate compounds, clinical efficacy, and safety parameters are not provided in the abstract.
Cited by
- supports Approximately 30% of frontotemporal dementia cases are genetic or familial, while 70% of cases are sporadic.